LLY

1,076.73

-2.38%↓

JNJ

222.23

-1.31%↓

ABBV

211.54

-2.95%↓

UNH

377.82

-0.22%↓

MRK

114.45

-3.5%↓

LLY

1,076.73

-2.38%↓

JNJ

222.23

-1.31%↓

ABBV

211.54

-2.95%↓

UNH

377.82

-0.22%↓

MRK

114.45

-3.5%↓

LLY

1,076.73

-2.38%↓

JNJ

222.23

-1.31%↓

ABBV

211.54

-2.95%↓

UNH

377.82

-0.22%↓

MRK

114.45

-3.5%↓

LLY

1,076.73

-2.38%↓

JNJ

222.23

-1.31%↓

ABBV

211.54

-2.95%↓

UNH

377.82

-0.22%↓

MRK

114.45

-3.5%↓

LLY

1,076.73

-2.38%↓

JNJ

222.23

-1.31%↓

ABBV

211.54

-2.95%↓

UNH

377.82

-0.22%↓

MRK

114.45

-3.5%↓

Strona główna・Stock List・Cytokinetics Inc

Cytokinetics Inc

Open

SectorHealthcare

73.3 -4.54

Buy Sell

Overview

Share price change

24h

Current

Min

73.7

Max

76.34

Key metrics
By Trading Economics
Income	-23M -206M
Sales	1.6M 19M
EPS	-1.67
Profit margin	-1,064.485
Employees	673
EBITDA	112K -180M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+30.73% upside

Dividends
By Dow Jones
Next Earnings	6 sie 2026

Market Stats
By TradingEconomics
Market Cap	2.2B 10B
Previous open	77.84
Previous close	73.3

News Sentiment

By Acuity

26%

74%

44 / 344 Ranking in Healthcare

Cytokinetics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

31 maj 2026, 23:44 UTC

Market Talk

Nikkei May Remain Rangebound Amid Middle East Uncertainty -- Market Talk

31 maj 2026, 23:36 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

31 maj 2026, 23:36 UTC

Market Talk

Oil Rises Amid Few Signs of Strait of Hormuz's Reopening -- Market Talk

31 maj 2026, 23:36 UTC

Market Talk

Watch for Data-Center Investment in Australia's 1Q GDP Print -- Market Talk

31 maj 2026, 22:54 UTC

Acquisitions, Mergers, Takeovers

Berkshire Hathaway to Buy Homebuilder Taylor Morrison for $6.8 Billion -- WSJ

29 maj 2026, 23:08 UTC

Acquisitions, Mergers, Takeovers

Family Offices Bypass Private Equity and Go Direct -- Barrons.com

29 maj 2026, 23:06 UTC

Acquisitions, Mergers, Takeovers

After a Series of Sales, Hims Director Buys Company Shares -- Barrons.com

29 maj 2026, 20:53 UTC

Earnings

Oil Declines Lift Stocks to Fresh Records -- WSJ

29 maj 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

29 maj 2026, 20:33 UTC

Market Talk

Canada Meets Only One of Three Criteria To Declare Recession -- Market Talk

29 maj 2026, 20:11 UTC

Earnings

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29 maj 2026, 19:47 UTC

Earnings

These Were the Best and Worst S&P 500 Stocks in May -- Barrons.com

29 maj 2026, 19:36 UTC

Market Talk

U.S. Natural Gas Futures End Month With Gains -- Market Talk

29 maj 2026, 19:34 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

29 maj 2026, 19:34 UTC

Market Talk

Over Half of Canadian Industries Growing, Undermining Recession Talk -- Market Talk

29 maj 2026, 19:22 UTC

Market Talk

Oil Falls as U.S., Iran Expected to Reach Agreement -- Market Talk

29 maj 2026, 19:05 UTC

Acquisitions, Mergers, Takeovers

Universal Music Group Rejects $65 Billion Takeover Bid From Bill Ackman's Pershing Square -- Barrons.com

29 maj 2026, 18:19 UTC

Market Talk

Canada Technical Recession Chatter Rife But Per-Capita GDP Was Up -- Market Talk

29 maj 2026, 18:12 UTC

Acquisitions, Mergers, Takeovers

Universal Music Group Rejects $65 Billion Buyout Offer From Bill Ackman -- WSJ

29 maj 2026, 18:11 UTC

Market Talk

Canada Households Reaching Limit at Keeping Spending in Positive Territory -- Market Talk

29 maj 2026, 18:10 UTC

Market Talk

As BTC Long-Term Holders Rise, Short-Term Holders Flee -- Market Talk

29 maj 2026, 17:55 UTC

Earnings

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29 maj 2026, 17:55 UTC

Market Talk

NEAR Protocol Nearly Doubles in May -- Market Talk

29 maj 2026, 17:38 UTC

Market Talk

U.S. Oil Rig Count Rises for Fifth Straight Week -- Market Talk

29 maj 2026, 17:00 UTC

Earnings

Okta Stock Soars After Earnings. Results Aren't the Real Catalyst. -- Barrons.com

29 maj 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

29 maj 2026, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

29 maj 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

29 maj 2026, 16:02 UTC

Market Talk

Gold Extend Gains as Investors Await U.S.-Iran Deal News -- Market Talk

29 maj 2026, 15:55 UTC

Market Talk

Global Equities Roundup: Market Talk

Peer Comparison

Price change

Cytokinetics Inc Forecast

Price Target

By TipRanks

30.73% upside

12 Months Forecast

Average 100.35 USD 30.73%

High 140 USD

Low 67 USD

Based on 18 Wall Street analysts offering 12 month price targets forCytokinetics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

18 ratings

Buy

Hold

Sell

Based on 18 analysts giving stock ratings to Cytokinetics Inc - Dist in the past 3 months.

Sentiment

By Acuity

44 / 344 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Cytokinetics Inc

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. It develops small molecule drug candidates primarily engineered to impact muscle function and contractility. The company's drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. The company has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.